QMSR for IVD Manufacturers: Inspection Readiness, Lot Traceability, and Supplier Controls

The Quality Management System Regulation (QMSR) is FDA’s medical-device quality-system regulation in 21 CFR Part 820. Effective February 2, 2026, it incorporates ISO 13485:2016 by reference while retaining FDA-specific requirements. For an in vitro diagnostic (IVD) manufacturer, inspection readiness now means showing how the combined framework controls actual work: reagent and component acceptance, kit assembly, labeling, lot release, distribution, supplier oversight and complaint investigation.

A defensible system does not depend on a larger document library. It depends on connected records. An investigator should be able to select a released IVD lot and follow the evidence from purchasing through production, labeling and distribution, then test how a complaint or supplier issue would change the assessment. This guide turns that objective into practical preparation—not a promise that any inspection will end without observations.

Start with applicable scope and current inspection expectations

Part 820 applies to covered operations such as design, manufacture, packaging, labeling, storage, installation and servicing. A company performing only some of those operations must comply with the requirements applicable to its activities. Map the devices, sites, contract manufacturers, laboratories and outsourced services within the system before assigning remediation work.

FDA’s QMSR overview explains the framework and its ISO 13485 alignment. Its inspection approach is described in Compliance Program 7382.850, which replaced QSIT for medical-device inspections when QMSR became effective. Update mock inspections to the current program instead of organizing evidence only around legacy subsystem names. The companion QMSR implementation guide provides the broader operating sequence.

Do not treat ISO certification as a substitute for FDA inspection readiness. FDA’s QMSR frequently asked questions clarify that a certificate does not exempt a manufacturer from inspection. Readiness work should therefore test both the incorporated quality-system clauses and the FDA-specific provisions in current Part 820.

Build lot genealogy around the released IVD

Lot traceability is more than assigning a number. For an IVD kit, connect incoming critical materials, reagent batches, assembly or filling operations, quality-control results, approved labels, release authorization and distribution destinations. The record should show which components were used, which version of instructions applied and who accepted each stage.

IVD labeling adds product-specific obligations. 21 CFR 809.10 requires a lot or control number from which the complete manufacturing history can be determined, together with applicable expiration, storage and handling information. FDA’s IVD labeling requirements page also addresses traceability for multiunit products, instruments and system components. A practical genealogy test should include kit components and instrument subassemblies, not only reagent batches.

Part 820’s labeling and packaging controls require documented accuracy checks before release or storage, including applicable identification, expiration, storage, handling and additional-processing instructions. Keep label approval, line clearance, inspection and reconciliation evidence connected to the device history record. If a label revision or component substitution occurs, the change record should identify affected lots and unfinished inventory.

Treat supplier control as an evidence chain

CP 7382.850 identifies outsourcing and purchasing as an inspection area. The central question is whether outsourced processes and purchased products are effectively monitored and controlled to achieve conformity. An approved-supplier list is useful, but it does not by itself demonstrate control.

Organize evidence into three linked layers. First, qualification: define supplier criticality, required capabilities, quality terms and approval rationale. Second, purchasing information: translate product and regulatory requirements into specifications, acceptance activities, change-notification obligations and record expectations. Third, monitoring: evaluate incoming results, complaints, nonconformities, delivery issues and audit findings against defined criteria.

For a critical antibody, nucleic-acid component, calibrator, plastic consumable or contract manufacturing service, test whether the team can show the current specification, the accepted lot, the certificate or inspection result and the supplier’s performance history. When a supplier changes raw material, equipment, site or test method, the manufacturer’s review should address verification, validation, labeling and regulatory impact before implementation—not after a field problem.

Connect complaints and quality signals to the lot

Complaint handling should not stop at a narrative investigation. Under the applicable Part 820 complaint-record provisions, retain the device identification, complaint details, investigation results, corrective actions and replies as required. For IVDs, link the complaint to the affected lot genealogy, supplier evidence, storage conditions, labeling version and distribution scope. That connection supports decisions about containment, correction, removal, supplier escalation and broader process review.

Routine quality-system traceability should not be confused with FDA’s separate device-tracking requirements under Part 821, which apply when the applicable conditions or an FDA tracking order are met. The practical objective is different: make the records necessary to evaluate the specific IVD and its risk available, coherent and retrievable.

Run a record-level inspection rehearsal

Select one released lot and one complaint or supplier change. Ask cross-functional staff to retrieve the evidence without relying on one local expert. Check that revisions, dates, approvals and electronic-record controls are consistent. The six-QMS-area inspection guide can help organize the exercise, while the Form 483 prevention guide focuses on closing avoidable evidence gaps.

Download the IVD evidence register

Download the editable IVD QMSR Inspection Readiness Evidence Register.xlsx. Use it to assign owners, record sample evidence, test lot genealogy and track supplier-control gaps. It is a preparation aid, not an FDA form, certification tool or substitute for device-specific regulatory judgment.

• Scope, sites and outsourced activities are mapped to applicable requirements.
• One released lot can be reconstructed from incoming material through distribution.
• IVD label checks include lot identification, expiry, storage and handling controls.
• Critical suppliers have current specifications, acceptance evidence and monitoring results.
• Complaint and change records identify affected lots and require documented closure.

FDA primary sources

Start with FDA’s QMSR overview, QMSR frequently asked questions and Inspection of Medical Device Manufacturers compliance program. Use current 21 CFR Part 820 for binding quality-system text, 21 CFR 809.10 for IVD labeling and FDA’s IVD labeling requirements for product-specific labeling explanations.

Turn fragmented evidence into controlled execution

Use MedTech Copilot to organize lot genealogy, supplier evidence, quality records and remediation actions around traceable decisions. Qualified human owners remain responsible for applicability, release and regulatory determinations. The goal is practical, evidence-backed, inspection-ready implementation—not automated assurance of compliance.